| CAS NO: | 1421-65-4 |
| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
| 5g | 电议 |
| Cas No. | 1421-65-4 |
| 别名 | 盐酸左旋多巴甲酯,3,4-Dihydroxyphenylalanine methyl ester,LDME,Levodopa methyl ester,ST 41769 |
| 化学名 | 3-hydroxy-L-tyrosine, methyl ester, monohydrochloride |
| Canonical SMILES | OC1=C(O)C=CC(C[C@H](N)C(OC)=O)=C1.Cl |
| 分子式 | C10H13NO4o HCl |
| 分子量 | 247.7 |
| 溶解度 | ≥ 13.6mg/mL in DMSO |
| 储存条件 | Store at -20℃ |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | L-DOPA methyl ester is a dopamine D1 receptor agonist. The D1 subtype of the dopamine receptor is the most abundant dopamine receptor in the central nervous system. D1 receptors can regulate neuronal growth and development, mediate some behavioral responses, and modulate dopamine receptor D2-mediated events. In vitro: L-DOPA methyl ester is a neutral derivative of L-DOPA formulated for increased solubility compared to the parent compound. L-DOPA is a metabolic precursor of dopamine that is capable of crossing the blood brain barrier to act as a dopamine D1 receptor agonist [1]. In vivo: On intraperitoneal or subcutaneous administration to mice L-Dopa methyl ester was found to be equivalent to L-Dopa in reversing reserpine-induced akinesia and producing contraversive circling behaviour in rats. On oral administration the methyl ester was even more active. The administration of L-Dopa or the methyl ester had equivalent changes of metabolite levels in striatal and mesolimbic dopamine, homovanillic acid, as well as 3,4-dihydroxyphenylacetic acid [2]. Clinical trial: Five sublingual and five subcutaneous doses of L-dopa methyl ester were given to seven patients with idiopathic Parkinson's disease and motor fluctuations. Motor assessments were conducted using the modified Webster scale. Results showed that two patients switched "on" with subcutaneous L-dopa methyl ester with the same quality and duration of therapeutic effect seen after their oral levodopa doses. The time from injection to full switch "on" was 60 minutes in both patients. Two patients had no effect over the entire observation period of 90 minutes and another one experienced onset-of-dose dyskinesias continuing for 110 minutes without ever switching fully "on" [3]. References: |
m.cnreagent.com